Limits...
Association between pretreatment Glasgow prognostic score and gastric cancer survival and clinicopathological features: a meta-analysis.

Zhang CX, Wang SY, Chen SQ, Yang SL, Wan L, Xiong B - Onco Targets Ther (2016)

Bottom Line: The results indicated that pretreatment high GPS (HGPS) predicted poor overall survival (hazard ratio =1.51, 95% CI: 1.37-1.66, P<0.01) and disease-free survival (hazard ratio =1.45, 95% CI: 1.26-1.68, P<0.01) in GC patients.Pretreatment HGPS was also significantly associated with advanced tumor-node-metastasis stage (odds ratio [OR] =3.09, 95% CI: 2.11-4.53, P<0.01), lymph node metastasis (OR =4.60, 95% CI: 3.23-6.56, P<0.01), lymphatic invasion (OR =3.04, 95% CI: 2.00-4.62, P<0.01), and venous invasion (OR =3.56, 95% CI: 1.81-6.99, P<0.01).Our meta-analysis indicated that pretreatment HGPS could be a predicative factor of poor survival outcome and clinicopathological features for GC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, Wuhan, Hubei, People's Republic of China.

ABSTRACT

Background: Glasgow prognostic score (GPS) is widely known as a systemic inflammatory-based marker. The relationship between pretreatment GPS and gastric cancer (GC) survival and clinicopathological features remains controversial. The aim of the study was to conduct a meta-analysis of published studies to evaluate the association between pretreatment GPS and survival and clinicopathological features in GC patients.

Methods: We searched PubMed, Embase, MEDLINE, and BioMed databases for relevant studies. Combined analyses were used to assess the association between pretreatment GPS and overall survival, disease-free survival, and clinicopathological parameters by Stata Version 12.0.

Results: A total of 14 studies were included in this meta-analysis, including 5,579 GC patients. The results indicated that pretreatment high GPS (HGPS) predicted poor overall survival (hazard ratio =1.51, 95% CI: 1.37-1.66, P<0.01) and disease-free survival (hazard ratio =1.45, 95% CI: 1.26-1.68, P<0.01) in GC patients. Pretreatment HGPS was also significantly associated with advanced tumor-node-metastasis stage (odds ratio [OR] =3.09, 95% CI: 2.11-4.53, P<0.01), lymph node metastasis (OR =4.60, 95% CI: 3.23-6.56, P<0.01), lymphatic invasion (OR =3.04, 95% CI: 2.00-4.62, P<0.01), and venous invasion (OR =3.56, 95% CI: 1.81-6.99, P<0.01).

Conclusion: Our meta-analysis indicated that pretreatment HGPS could be a predicative factor of poor survival outcome and clinicopathological features for GC patients.

No MeSH data available.


Related in: MedlinePlus

The forest plot between pretreatment GPS and OS in GC patients.Abbreviations: GPS, Glasgow prognostic score; OS, overall survival; GC, gastric cancer; HR, hazard ratio; CI, confidence interval; HGPS, high Glasgow prognostic score; LGPS, low Glasgow prognostic score.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4930270&req=5

f2-ott-9-3883: The forest plot between pretreatment GPS and OS in GC patients.Abbreviations: GPS, Glasgow prognostic score; OS, overall survival; GC, gastric cancer; HR, hazard ratio; CI, confidence interval; HGPS, high Glasgow prognostic score; LGPS, low Glasgow prognostic score.

Mentions: There were 13 studies reporting the relationship between pretreatment GPS and OS in GC patients.11,12,16–22,24–27 With no obvious heterogeneity (I2=31.9%, P=0.13), the pooled HR of 1.51 (95% CI: 1.37–1.66, P<0.01) implied that GC patients with HGPS were expected to have poor OS (Figure 2). Then, we conducted subgroup analysis according to confounders such as predominant treatment, country, sample size, and NOS score.


Association between pretreatment Glasgow prognostic score and gastric cancer survival and clinicopathological features: a meta-analysis.

Zhang CX, Wang SY, Chen SQ, Yang SL, Wan L, Xiong B - Onco Targets Ther (2016)

The forest plot between pretreatment GPS and OS in GC patients.Abbreviations: GPS, Glasgow prognostic score; OS, overall survival; GC, gastric cancer; HR, hazard ratio; CI, confidence interval; HGPS, high Glasgow prognostic score; LGPS, low Glasgow prognostic score.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4930270&req=5

f2-ott-9-3883: The forest plot between pretreatment GPS and OS in GC patients.Abbreviations: GPS, Glasgow prognostic score; OS, overall survival; GC, gastric cancer; HR, hazard ratio; CI, confidence interval; HGPS, high Glasgow prognostic score; LGPS, low Glasgow prognostic score.
Mentions: There were 13 studies reporting the relationship between pretreatment GPS and OS in GC patients.11,12,16–22,24–27 With no obvious heterogeneity (I2=31.9%, P=0.13), the pooled HR of 1.51 (95% CI: 1.37–1.66, P<0.01) implied that GC patients with HGPS were expected to have poor OS (Figure 2). Then, we conducted subgroup analysis according to confounders such as predominant treatment, country, sample size, and NOS score.

Bottom Line: The results indicated that pretreatment high GPS (HGPS) predicted poor overall survival (hazard ratio =1.51, 95% CI: 1.37-1.66, P<0.01) and disease-free survival (hazard ratio =1.45, 95% CI: 1.26-1.68, P<0.01) in GC patients.Pretreatment HGPS was also significantly associated with advanced tumor-node-metastasis stage (odds ratio [OR] =3.09, 95% CI: 2.11-4.53, P<0.01), lymph node metastasis (OR =4.60, 95% CI: 3.23-6.56, P<0.01), lymphatic invasion (OR =3.04, 95% CI: 2.00-4.62, P<0.01), and venous invasion (OR =3.56, 95% CI: 1.81-6.99, P<0.01).Our meta-analysis indicated that pretreatment HGPS could be a predicative factor of poor survival outcome and clinicopathological features for GC patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors and Hubei Cancer Clinical Study Center, Wuhan, Hubei, People's Republic of China.

ABSTRACT

Background: Glasgow prognostic score (GPS) is widely known as a systemic inflammatory-based marker. The relationship between pretreatment GPS and gastric cancer (GC) survival and clinicopathological features remains controversial. The aim of the study was to conduct a meta-analysis of published studies to evaluate the association between pretreatment GPS and survival and clinicopathological features in GC patients.

Methods: We searched PubMed, Embase, MEDLINE, and BioMed databases for relevant studies. Combined analyses were used to assess the association between pretreatment GPS and overall survival, disease-free survival, and clinicopathological parameters by Stata Version 12.0.

Results: A total of 14 studies were included in this meta-analysis, including 5,579 GC patients. The results indicated that pretreatment high GPS (HGPS) predicted poor overall survival (hazard ratio =1.51, 95% CI: 1.37-1.66, P<0.01) and disease-free survival (hazard ratio =1.45, 95% CI: 1.26-1.68, P<0.01) in GC patients. Pretreatment HGPS was also significantly associated with advanced tumor-node-metastasis stage (odds ratio [OR] =3.09, 95% CI: 2.11-4.53, P<0.01), lymph node metastasis (OR =4.60, 95% CI: 3.23-6.56, P<0.01), lymphatic invasion (OR =3.04, 95% CI: 2.00-4.62, P<0.01), and venous invasion (OR =3.56, 95% CI: 1.81-6.99, P<0.01).

Conclusion: Our meta-analysis indicated that pretreatment HGPS could be a predicative factor of poor survival outcome and clinicopathological features for GC patients.

No MeSH data available.


Related in: MedlinePlus